NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH, SWITZERLAND / ACCESSWIRE / December 29, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...

Related Keywords

Switzerland ,United States ,Ukraine ,United Kingdom ,Bern ,France ,Paris ,France General ,Zurich ,Züsz ,Canada ,Swiss ,French ,American ,Elena Thyen Pighin ,Marianne Lambertson ,Allouch Aknin ,Florence Allouche Aknin ,Claudio Bassetti ,Claudio La Bassetti ,Alex Zwyer ,Allouche Aknin ,European Neurological Society ,Neurology Department ,Aexon Lab Dual Orexin Receptor Agonists ,Nasdaq ,American Academy Of Sleep Medicine ,Ongoing Business Development ,Research Society ,Patient Program ,European Sleep Research Society ,Aexon Labs Inc ,Caligor Coghlan Pharma Services ,Bern University Hospital ,European Academy Of Neurology ,Pharmaceutics Ltd ,University Paris City ,University Of Bern ,Exchange Commission ,Aexon Lab ,Chief Executive Officer ,Middle East ,Central Nervous System ,American Academy ,Sleep Medicine ,Sleep Research Society ,Institutional Review Board ,Aexon Labs ,Kleine Levin Syndrome ,Global Sleep Medicine Market ,Chief Financial Officer ,Medical Faculty ,European Academy ,Sorbonne Venture ,Mercure Entrepreneurs Award ,Professor Allouche Aknin ,Named Patient Program ,Durbin Global ,Expanded Access ,